New treatments for hepatitis C: Life cycle lessons

Ilan S. Weisberg, Samuel H. Sigal, Ira M. Jacobson

Research output: Contribution to journalReview article

Abstract

Despite progressive advances, therapy with interferon and ribavirin has been the mainstay of treatment for chronic hepatitis C for over a decade. With the development of in vitro systems to study viral replication, there have been great advances in the understanding of hepatitis C biology, and these advances, in turn, are allowing the development of specifically targeted antiviral therapies. This review employs our current understanding of the hepatitis C replicative life cycle as a framework on which to discuss new antiviral agents under clinical investigation.

Original languageEnglish (US)
Pages (from-to)75-82
Number of pages8
JournalCurrent Hepatitis Reports
Volume6
Issue number2
StatePublished - May 2007
Externally publishedYes

Fingerprint

Hepatitis C
Life Cycle Stages
Antiviral Agents
Ribavirin
Chronic Hepatitis C
Interferons
Therapeutics
In Vitro Techniques

ASJC Scopus subject areas

  • Hepatology
  • Virology

Cite this

Weisberg, I. S., Sigal, S. H., & Jacobson, I. M. (2007). New treatments for hepatitis C: Life cycle lessons. Current Hepatitis Reports, 6(2), 75-82.

New treatments for hepatitis C : Life cycle lessons. / Weisberg, Ilan S.; Sigal, Samuel H.; Jacobson, Ira M.

In: Current Hepatitis Reports, Vol. 6, No. 2, 05.2007, p. 75-82.

Research output: Contribution to journalReview article

Weisberg, IS, Sigal, SH & Jacobson, IM 2007, 'New treatments for hepatitis C: Life cycle lessons', Current Hepatitis Reports, vol. 6, no. 2, pp. 75-82.
Weisberg, Ilan S. ; Sigal, Samuel H. ; Jacobson, Ira M. / New treatments for hepatitis C : Life cycle lessons. In: Current Hepatitis Reports. 2007 ; Vol. 6, No. 2. pp. 75-82.
@article{ada5e6dcdf324630859701ac01eb084d,
title = "New treatments for hepatitis C: Life cycle lessons",
abstract = "Despite progressive advances, therapy with interferon and ribavirin has been the mainstay of treatment for chronic hepatitis C for over a decade. With the development of in vitro systems to study viral replication, there have been great advances in the understanding of hepatitis C biology, and these advances, in turn, are allowing the development of specifically targeted antiviral therapies. This review employs our current understanding of the hepatitis C replicative life cycle as a framework on which to discuss new antiviral agents under clinical investigation.",
author = "Weisberg, {Ilan S.} and Sigal, {Samuel H.} and Jacobson, {Ira M.}",
year = "2007",
month = "5",
language = "English (US)",
volume = "6",
pages = "75--82",
journal = "Current Hepatitis Reports",
issn = "1540-3416",
publisher = "Springer Publishing Company",
number = "2",

}

TY - JOUR

T1 - New treatments for hepatitis C

T2 - Life cycle lessons

AU - Weisberg, Ilan S.

AU - Sigal, Samuel H.

AU - Jacobson, Ira M.

PY - 2007/5

Y1 - 2007/5

N2 - Despite progressive advances, therapy with interferon and ribavirin has been the mainstay of treatment for chronic hepatitis C for over a decade. With the development of in vitro systems to study viral replication, there have been great advances in the understanding of hepatitis C biology, and these advances, in turn, are allowing the development of specifically targeted antiviral therapies. This review employs our current understanding of the hepatitis C replicative life cycle as a framework on which to discuss new antiviral agents under clinical investigation.

AB - Despite progressive advances, therapy with interferon and ribavirin has been the mainstay of treatment for chronic hepatitis C for over a decade. With the development of in vitro systems to study viral replication, there have been great advances in the understanding of hepatitis C biology, and these advances, in turn, are allowing the development of specifically targeted antiviral therapies. This review employs our current understanding of the hepatitis C replicative life cycle as a framework on which to discuss new antiviral agents under clinical investigation.

UR - http://www.scopus.com/inward/record.url?scp=34249877984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249877984&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:34249877984

VL - 6

SP - 75

EP - 82

JO - Current Hepatitis Reports

JF - Current Hepatitis Reports

SN - 1540-3416

IS - 2

ER -